

1 **Title: Genomic and Virological Characterization of SARS-CoV-2 Variants in a Subset of**
2 **Unvaccinated and Vaccinated U.S. Military Personnel**

3 **Authors:** Darci R. Smith^{1*}, Christopher Singh^{1,2}, Jennetta Green¹, Matthew R. Lueder^{3,4},
4 Catherine E. Arnold^{3,5}, Logan J. Voegtly^{3,4}, Kyle A. Long^{3,4}, Gregory K. Rice^{3,4}, Andrea
5 Luquette^{3,4}, Haven Miner^{3,4}, Lindsay Glang^{3,4}, Andrew Bennett^{3,4}, Robin Miller^{3,4}, Francisco
6 Malagon^{3,4}, Regina Z. Cer³, and Kimberly A. Bishop-Lilly^{3*}

7 ¹Naval Medical Research Center, Biological Defense Research Directorate, Microbiology and
8 Immunology Department, Fort Detrick, MD, USA

9 ²Parsons, Centreville, VA, USA

10 ³Naval Medical Research Center, Biological Defense Research Directorate, Genomics and
11 Bioinformatics Department, Fort Detrick, MD, USA

12 ⁴Leidos, Reston, VA, USA

13 ⁵Defense Threat Reduction Agency, Fort Belvoir, VA, USA

14 *Corresponding authors: Darci R. Smith (darci.r.smith.civ@mail.mil) and Kimberly A. Bishop-
15 Lilly (Kimberly.a.bishop-lilly.civ@mail.mil)

16

17 **Abstract**

18 The emergence of SARS-CoV-2 variants complicates efforts to control the COVID-19
19 pandemic. Increasing genomic surveillance of SARS-CoV-2 is imperative for early detection of
20 emerging variants, to trace the movement of variants, and to monitor effectiveness of
21 countermeasures. Additionally, determining the amount of viable virus present in clinical

22 samples is helpful to better understand the impact these variants have on viral shedding. In this
23 study, we analyzed nasal swab samples collected between March 2020 and early November 2021
24 from a cohort of United States (U.S.) military personnel and healthcare system beneficiaries
25 stationed worldwide as a part of the Defense Health Agency's (DHA) Global Emerging
26 Infections Surveillance (GEIS) program. SARS-CoV-2 quantitative real time reverse-
27 transcription PCR (qRT-PCR) positive samples were characterized by next-generation
28 sequencing and a subset was analyzed for isolation and quantification of viable virus. Not
29 surprisingly, we found that the Delta variant is the predominant strain circulating among U.S.
30 military personnel beginning in July 2021 and primarily represents cases of vaccine
31 breakthrough infections (VBIs). Among VBIs, we found a 50-fold increase in viable virus in
32 nasal swab samples from Delta variant cases when compared to cases involving other variants.
33 Notably, we found a 40-fold increase in viable virus in nasal swab samples from VBIs involving
34 Delta as compared to unvaccinated personnel infected with other variants prior to the availability
35 of approved vaccines. This study provides important insight about the genomic and virological
36 characterization of SARS-CoV-2 isolates from a unique study population with a global presence.

37

38 **Keywords:** Emerging SARS-CoV-2 variants, viable virus, vaccine breakthrough infection,
39 sequencing, nasal swabs

40

41 **Impact:** The COVID-19 pandemic is currently a leading cause of death globally and new
42 SARS-CoV-2 variants continue to emerge. Genomic surveillance of variants is necessary to
43 characterize mutations that could affect transmissibility and spread, antigenicity or virulence.

44 Furthermore, wet lab studies are necessary to evaluate how genetic differences may affect viral
45 fitness and transmissibility. The Delta variant is currently the predominant strain globally and
46 determining factors that drive its ability to spread rapidly is important. In this study, we
47 characterized SARS-CoV-2 positive samples from U.S. military personnel and their beneficiaries
48 by next-generation sequencing and isolation of viable virus. Consistent with other studies, we
49 found higher levels of infectious virus from Delta samples when compared to non-Delta
50 infections. Strikingly, we found the difference in titer between Delta and other strains to be so
51 profound as to be unaffected by vaccination status, suggesting that increased transmissibility of
52 the Delta variant is in part due to higher amounts of virus shedding. This helps explain the rapid
53 spread of the Delta variant and provides the impetus to increase control measures such as
54 vaccination, boosters, masking and distancing requirements. It will be necessary to continue
55 genomic and virological characterization of new variants, such as Omicron.

56

57 **Introduction**

58 The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
59 causative agent of coronavirus disease 2019 (COVID-19), has led to a historic global pandemic.
60 Multiple SARS-CoV-2 genetic variants are circulating globally, some of which have mutations
61 of concern or mutations of interest that could impact transmissibility and spread, antigenicity or
62 virulence (1). The World Health Organization (WHO) classifies many of these as variants of
63 concern (VOC) or variants of interest (VOI) based on mutations that may impact SARS-CoV-2
64 countermeasures, including vaccines, therapeutics, and diagnostics. Current VOC as defined by
65 the WHO include B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and most
66 recently, B.1.1.529 (Omicron), which was designated as a VOC on 26 November 2021. The

67 Alpha variant was initially detected in the United Kingdom at the end of 2020 and remained as
68 the dominant strain globally until May 2021 (2). The Delta variant was first detected in India and
69 became a VOI in April 2021 and a VOC in May 2021 when it became the dominant strain
70 identified worldwide (3). The Delta variant is estimated to be more transmissible than the Alpha
71 variant, is less sensitive to neutralizing antibodies, and causes increased hospitalization rates
72 mainly in unvaccinated individuals (4-6). There are currently multiple vaccines in use either with
73 FDA approval or emergency use authorization (EUA) that have shown efficacy, however
74 vaccine breakthrough infections (VBIs) do occur and may increase with the emergence of novel
75 variants (7).

76 Quantitative real time reverse-transcription PCR (qRT-PCR) is the benchmark method
77 for COVID-19 diagnosis, but an important limitation of this approach is the assay only detects
78 RNA and does not detect infectious virus. This can be problematic since several studies have
79 described the persistence of SARS-CoV-2 RNA within different body sites (8-10) and viral RNA
80 levels as a measurement of viral load does not always correlate to the amount of viable virus in a
81 given sample. Quantitative assays that measure replication competent virus are important for
82 determining infectious viral titers in clinical samples, which is critical to informing infection
83 prevention and control guidelines for current and future SARS-CoV-2 variants.

84 Detection of infectious virus is determined by *in vitro* viral culture on susceptible cell
85 lines. However, the ability of viral culture methods to provide insight on infectious shedding is
86 hampered by the fact that this method is labor-intensive and requires biosafety level 3 (BSL-3)
87 facilities for SARS-CoV-2. There are also assay variables such as the cell line and methods used
88 to quantify the amount of virus. Vero cells and their subclones or derivatives are commonly used
89 to culture SARS-CoV-2 and Vero E6 cells expressing human transmembrane serine protease 2

90 (TMPRSS2) have demonstrated enhanced susceptibility and isolation of SARS-CoV-2 (11).
91 Plaque or median tissue culture infectious dose (TCID₅₀) assays are commonly used to quantify
92 viable virus, but new methods have been described like the S-Fuse assay that uses a cell reporter
93 system and is based on the detection of GFP positive syncytia formation between infected and
94 neighboring cells (12).

95 While some studies have described the amount of viable virus shed by individuals
96 infected with the various SARS-CoV-2 variants (12-14), more studies are needed to better
97 characterize infectious virus levels in vaccinated and unvaccinated individuals. This is especially
98 important because each study uses different methods and focuses on different populations of
99 individuals from different geographic locations. In this study, we analyzed nasal swab samples
100 collected between March 2020 and early November 2021 from a cohort of U.S. military
101 personnel and beneficiaries stationed worldwide as a part of the DHA's GEIS program. SARS-
102 CoV-2 qRT-PCR positive samples were characterized by next-generation sequencing and a
103 subset was analyzed for isolation and quantification of viable virus. Following the EUA approval
104 of the COVID-19 vaccines, samples were collected from vaccinated individuals to characterize
105 VBIs. This study provides unique insight about the genomic and virological characteristics of
106 SARS-CoV-2 isolates from a generally healthy population with a global presence that spans
107 from the beginning of the pandemic to early November 2021.

108

109 **Methods**

110 **Genome sequencing**

111 Viral genome sequencing was conducted on the Illumina MiSeq platform using the ARTIC
112 nCoV-2019 Sequencing protocol (15) and the YouSeq SARS-CoV-2 Coronavirus NGS Library
113 prep kit (YouSeq). Approximately 100ng of RNA was reverse-transcribed as in the protocol,
114 however the YouSeq reverse transcriptase was replaced with SuperScript IV (ThermoFisher
115 Scientific). cDNA was amplified using multiplex PCR and either the associated ARTIC primer
116 pools or YouSeq primer pools. Libraries prepared via the ARTIC protocol were cleaned using
117 1x AMPure XP beads (Beckman Coulter) and re-suspended in nuclease free molecular grade
118 water. The samples were then processed following the QiaSeq FX protocol (Qiagen) and
119 libraries were completed. Libraries were quality-checked using an Agilent Bioanalyzer High
120 sensitivity kit (Agilent) and quantified using the Qubit DNA High Sensitivity assay
121 (ThermoFisher Scientific) prior to sequencing using Illumina MiSeq v3 2x300 chemistry
122 (Illumina).

123

124 **Bioinformatics Analyses**

125 Viral Amplicon Illumina Workflow (VAIW) was used to collate SARS-CoV-2 consensus
126 genomes (16). Briefly, Illumina reads were quality trimmed and filtered to >Q20 and minimum
127 length of 50 bp using bbmap (17). Paired reads were merged using bbmerge with default
128 settings (18). Trimmed, filtered, and merged reads were aligned to the Wuhan reference genome
129 (NCBI GenBank accession NC_045512.2/MN908947.3) using bbmap with local alignment and
130 maximum insertion/deletion of 500 bp (17). Primers were trimmed from sequences using
131 align_trim from ARTIC workflow/pipeline (19). Once a high quality consensus genome was
132 obtained, Single Nucleotide Variants (SNVs) were determined using SAMtools mpileup (20)
133 and iVar (Intrahost variant analysis of replicates) (21) using a minimum frequency of 0.3 and a

134 minimum read depth of 10 (22).(23-25) Lineage information was derived using Pangolin
135 (Phylogenetic Assignment of Named Global Outbreak LINEages) v3.1.16; [github.com/hCoV-](https://github.com/hCoV-2019/pangolin)
136 [2019/pangolin](https://github.com/hCoV-2019/pangolin)) (26)

137

138 **Virus culture**

139 Patient samples were cultured for SARS-CoV-2 using a standard plaque assay on Vero E6 cells
140 expressing TMPRSS2 [4] in six-well plates and a cytopathic effect (CPE) assay on Vero
141 E6/TMPRSS2 cells in T25 cm² flasks. For the plaque assay, duplicate wells were infected with
142 0.2mL aliquots from serial 10-fold dilutions in Minimum Essential Medium (MEM) followed by
143 a 1 hr incubation at 37°C, 5% CO₂ to allow virus adsorption to occur. After incubation, cells
144 were overlaid with MEM containing 0.5% agar supplemented with 5% heat-inactivated FBS, 1%
145 Penicillin/Streptomycin and incubated for 48 hr at 37 °C, 5% CO₂. Cells were fixed in 10%
146 formalin prior to staining with crystal violet. For the CPE assay, cells were seeded in T25 cm²
147 flasks and each flask was infected with 0.5mL aliquots from a 1:10 dilution in Dulbecco's
148 Modified Eagle Medium (DMEM) followed by a 1 hr incubation at 37°C, 5% CO₂. After
149 incubation, 5mL of DMEM supplemented with 5% heat-inactivated FBS, 1%
150 Penicillin/Streptomycin was incubated for 4 days at 37°C, 5% CO₂. CPE was monitored daily.
151 After 4 days, supernatant was passed onto fresh cells to allow additional time to amplify. The
152 presence of SARS-CoV-2 was confirmed by lateral flow immunoassay using the Quidel Sofia 2
153 analyzer and/or qRT-PCR.

154

155 **Statistical analysis**

156 Statistical analysis was performed using GraphPad Prism. Tukey’s multiple comparisons test was
157 used to compare the amount of viable virus between the unvaccinated and vaccinated groups.

158

159 **Results**

160 We have sequenced over 2,300 nasal swab samples collected from March 2020 until early
161 November 2021 and of those, we produced 1,304 coding complete genomes for which we then
162 determined the Pango lineages (Figure 1). Smaller numbers of samples were received early in the
163 pandemic compared to after the variants began to emerge when there was more impetus to
164 sequence a greater number of samples. The first samples sequenced in March and April 2020
165 were similar to strains at the root of the pandemic (lineage A and sublineages) and are classified
166 as A.1, A.3 etc., collectively designated as Pango lineage “other” in Figure 1A and C. The
167 “other” category also contains B lineages and was used for any lineage with 12 or less
168 representatives. The large European lineage B.1 was detected in six samples in April 2020. In
169 February 2021, there was a strong commitment within the DoD to sequence a greater number of
170 samples with the rationale that it is important to continually perform genomic surveillance of the
171 SARS-CoV-2 genome for early detection of emerging variants and to monitor variant cases in
172 several geographic locations. The VOC B.1.1.7 (Alpha) was the predominant strain detected
173 between February and June 2021. Many military personnel were considered fully vaccinated
174 during this same timeframe and some of these samples represent cases of VBI. The former VOC,
175 B.1.526 (Iota), which is a lineage predominantly circulating in New York, was detected from
176 March to June 2021 in 29 samples. The VOC, B.1.617.2 (Delta) was first detected in May 2021
177 in one sample collected from Portsmouth, Virginia. An increasing number of B.1.617.2 (Delta)
178 was detected starting in June 2021 and by July 2021 was the dominant variant detected in all

179 samples received. Multiple sublineages of B.1.617.2 were detected which increased over time
180 (Figure 1B and D). The “other” category for Figure 1B and D was used for any sublineage with 5
181 or less representatives. The Omicron variant was not detected during the timeframe of our
182 current study.

183 A subset of samples were selected to determine if viable virus was present where we
184 compared viral titers in samples collected from unvaccinated individuals and cases of VBI
185 (Figure 2). A summary of the results broken down by Pango lineage is shown in Table 1 and 2
186 for unvaccinated and vaccinated individuals, respectively. We detected viable virus in 25
187 samples received from unvaccinated personnel collected between March 2020 and January 2021,
188 which is prior to the emergence of VOCs. The mean amount of virus detected in unvaccinated
189 personnel was 3.2 log₁₀ PFU/mL, which is similar to the amount of virus detected from VBIs
190 associated with all variants except for Delta (3.1 log₁₀ PFU/mL). Significantly more virus was
191 detected in VBIs associated with the Delta variant when compared to unvaccinated personnel.
192 The mean amount of virus detected in VBIs associated with the Delta variant was 4.6 log₁₀
193 PFU/mL, which was statistically significant by Tukey’s multiple comparisons test (p=0.0001)
194 when compared to the amount of virus detected in unvaccinated personnel prior to the emergence
195 of VOCs. In contrast to the unvaccinated samples, almost all the VBI samples associated with
196 the Delta variant had detectable virus that was above the level of detection for the plaque assay
197 and one sample had a titer as high as 7 log₁₀ PFU/mL. Samples from unvaccinated personnel
198 infected with the Delta variant were not available for this study since the majority of military
199 personnel were fully vaccinated when the Delta variant became the predominant strain. The
200 amount of virus detected in VBIs associated with the Delta variant compared to VBIs with other
201 variants was also statistically significant by Tukey’s multiple comparisons test (p=0.0132)

202 although with less power because of the low number of VBI samples associated with other
203 variants. The results are further broken down by vaccine manufacturer (Figure 2B) where we
204 continued to observe a statistically significant difference in viral titers for unvaccinated
205 individuals with non-Delta variants compared to samples from VBI associated with the Delta
206 variant from individuals that received the Pfizer ($p=0.0106$) and Johnson & Johnson ($p=0.0427$)
207 vaccines. Interestingly, VBI associated with the Delta variant that received the Moderna vaccine
208 was not statistically significant when compared to the unvaccinated group. This may be a
209 reflection of the limited number of samples in our analyses.

210

211 **Discussion**

212 The Delta variant displaced the Alpha variant and was identified as the predominant
213 strain in military personnel starting in July 2021. Currently, multiple sublineages of B.1.617.2
214 continue to be identified. A greater proportion of the VBI cases in our dataset have been
215 associated with the Delta variant, commensurate with its current preponderance in the population
216 at this point in time. We quantified the amount of viable virus in a subset of samples, and our
217 results suggest that the increased transmissibility of the Delta variant is in part due to higher
218 amounts of virus shedding. We detected 50-fold more infectious virus in VBIs involving Delta
219 compared to VBIs with other variants. We also detected 40-fold more infectious virus in VBIs
220 involving Delta compared to unvaccinated personnel infected with non-Delta variants.

221 Our results are similar to what has been reported for the rest of the population in the U.S.
222 where the Delta variant is currently the predominant strain and is more than twice as infectious
223 as previous strains. The improved viral fitness of the Delta variant has been associated with

224 mutations in the furin cleavage site that allow the virus to enter cells more efficiently (27, 28).
225 Another study found that four mutations in the nucleocapsid (N) protein, which is an important
226 protein for viral replication, improve the viruses' ability to form infectious particles. These four
227 mutations in N, which are universally found in more transmissible SARS-CoV-2 variants,
228 increased mRNA delivery and expression and two of the mutations produced more infectious
229 virus (29). This is consistent with other studies that found that samples from people infected with
230 the Delta variant have higher viral RNA levels and an increased duration of viral shedding
231 compared to samples collected from people infected with other variants (14, 30-32).
232 Furthermore, the levels of viral RNA from infected individuals have been shown to be similar for
233 vaccinated and unvaccinated individuals (14, 33).

234 Numerous studies measure viral load by the amount of viral RNA in a clinical sample,
235 but do not determine the amount of viable virus. This is likely due to the cumbersome nature of
236 the assays used to quantify levels of infectious virus coupled with the requirement to perform
237 these assays in a BSL-3 laboratory. However, a recent study found a significant amount of
238 variability in the relationship between viral titers for infectious virus and viral RNA levels (13).
239 Their results indicate that determining viral load by RNA levels in clinical samples may have
240 limitations and assays for viable virus should be included for emerging variants. Additionally,
241 they detected six times as much infectious virus for the same amount of RNA for Delta variant
242 samples compared to Alpha variant samples. Our results are similar where we found that the
243 Delta variant cases shed viable virus at higher levels. Similar levels of virus were detected from
244 unvaccinated personnel with non-Delta infections prior to the availability of vaccines granted
245 EUA and FDA approval compared to VBI due to other variants besides Delta. In contrast, 50-
246 fold more infectious virus was detected in samples from VBI due to Delta compared to VBIs

247 with other variants. When we analyzed our results by vaccine manufacturer, we continued to
248 detect significantly higher levels of infectious virus in samples from individuals who received
249 the Pfizer and Johnson & Johnson vaccines and experienced a VBI due to Delta when compared
250 to the unvaccinated personnel with non-Delta infections. Interestingly, VBI associated with the
251 Delta variant that received the Moderna vaccine was not statistically significant when compared
252 to the unvaccinated group. This may be a reflection of the limited number of samples in our
253 analyses. Another limitation of our study is the lack of access to metadata for the clinical
254 specimens, which affects our interpretation of the results by differences in age, pre-existing
255 conditions, and days from exposure or symptom onset. However, most of our samples did come
256 from active duty military personnel stationed worldwide who are considered young (age 18-40),
257 are required to maintain a physical fitness regimen and pass routine physicals, and are therefore
258 considered relatively healthy compared to the general population.

259 Other studies have also found that viable virus is more likely to be isolated from clinical
260 samples from Delta compared to Alpha (14). The authors do point out that there was a
261 significantly longer period between being considered fully vaccinated and when VBI with the
262 Delta variant occurred, which is similar to our results. However, our data demonstrating that we
263 detected 40-fold more infectious virus in VBIs involving Delta compared to unvaccinated
264 personnel with non-Delta infections prior to the availability of vaccines granted EUA and FDA
265 approval suggests that the increase in the amount of viable virus is due to the variant and not the
266 vaccination status. This is consistent with the study by Luo *et al.* that found the recovery of
267 infectious virus was significantly higher with the Delta variant compared to Alpha in both
268 vaccinated and unvaccinated groups (14).

269 Our results highlight the importance of characterizing the SARS-CoV-2 genome and
270 infectious viral titers of emerging variants isolated from unvaccinated and vaccinated personnel.
271 This work contributes to the growing body of evidence that the increased fitness of Delta is
272 primarily due to viral genetic determinants that increase infectivity or replication. This helps to
273 explain the rapid spread of the Delta variant and provides the impetus to increase control
274 measures such as vaccination, boosters, masking and distancing requirements to prevent ongoing
275 transmission. Furthermore, this study demonstrates the value of pairing genomic and virological
276 characterization when assessing novel SARS-CoV-2 variants. These parallel approaches should
277 be applied to newly emerging variants, such as Omicron, and other variants that may arise in the
278 future.

279

280 **Disclaimer**


281 The views expressed in this article are those of the authors and do not necessarily reflect the
282 official policy or position of the Department of Defense, the Navy, or the U.S. Government.
283 Several of the authors are U.S. Government employees. This work was prepared as part of their
284 official duties. Title 17 U.S.C. § 105 provides that ‘Copyright protection under this title is not
285 available for any work of the United States Government.’ Title 17 U.S.C. §101 defines a U.S.
286 Government work as a work prepared by a military service member or employee of the U.S.
287 Government as part of that person’s official duties.

288

289 **Acknowledgements**


290 We thank Justice Akuoku Frimpong, Kevin Schully, and Christina Farris for technical assistance
291 with the viral cultures. This study was supported by the Armed Forces Health Surveillance
292 Division (AFHSD), Global Emerging Infections Surveillance (GEIS) Branch, ProMIS IDs
293 P0013_AH_01.01, P0166_20_NM, P0093_21_NM, and P0199_21_NM to KABL as well as
294 Navy Work Unit Number (WUN) A1417.

295 Figures and Tables



296
297 **Figure 1: Pango lineages of circulating SARS-CoV-2 strains in the U.S. military before and**
298 **after implementation of the EUA vaccines.** A) Distribution of Pango lineages by month for all
299 samples; B) distribution of Delta variant sublineages by month; C) stacked chart displaying all
300 lineages per month; D) stacked chart displaying Delta variant sublineages by month.

301



302

303 **Figure 2: Infectious virus titers in unvaccinated and vaccinated personnel.** A) Viral titers in

304 nasal swabs determined by standard plaque assay; B) viral titers broken down by vaccine type.

305 Error bars represent the standard deviation, and the dashed line represents the detection limit of

306 the plaque assay. Symbols below this line were negative by the plaque assay, but positive by the

307 CPE assay. Asterisks indicate statistical significance determined by Tukey's multiple

308 comparisons test.

309

310

311

312 **Table 1: Summary of viable virus detection in nasal swab samples from unvaccinated**
313 **individuals broken down by Pango lineage**

Pango Lineage	Number of Samples	Range of Viable Virus (mean); PFU/mL (log₁₀)
B.1.2	1	3.0
B.1	18	1.4-5.9 (4.9)
B.1.1.9	4	1.4-3.7 (3.3)
B.6	2	2.8-2.9 (2.85)

314

315 **Table 2: Summary of viable virus detection in nasal swab samples from vaccinated**
316 **individuals broken down by Pango lineage**

Pango Lineage	Number of Samples	Range of Days Since Considered Fully Vaccinated (mean)	Range of Viable Virus (mean); PFU/mL (log₁₀)	Vaccine Manufacturer
B.1.2	2	13-29 (21)	3.0-3.4 (3.2)	Pfizer (2), Moderna (0), J&J (0)
B.1.351.5 (Beta)	4	24-38 (30)	1.4-4.3 (4.0)	Pfizer (1), Moderna (0), J&J (3)

B.1	1	18	1.4	Pfizer (0), Moderna (0), J&J (1)
B.1.525	1	31	3.7	Pfizer (0), Moderna (0), J&J (1)
B.1.617.2 (Delta)	47	34-193 (120)	1.4-7.0 (5.8)	Pfizer (24), Moderna (19), J&J (4)

317

318 References

- 319 1. Hadj Hassine I. Covid-19 vaccines and variants of concern: A review. *Rev Med Virol* (2021):e2313.
320 Epub 2021/11/11. doi: 10.1002/rmv.2313. PubMed PMID: 34755408.
- 321 2. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated
322 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* (2021) 372(6538). Epub
323 2021/03/05. doi: 10.1126/science.abg3055. PubMed PMID: 33658326; PubMed Central PMCID:
324 PMC8128288.
- 325 3. GISAID. hCov19 Variants [cited 2021 December 1]. Available from:
326 <https://www.gisaid.org/hcov19-variants/>.
- 327 4. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced
328 sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature* (2021) 596(7871):276-80.
329 Epub 2021/07/09. doi: 10.1038/s41586-021-03777-9. PubMed PMID: 34237773.
- 330 5. Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta KD, et al. Effect of Delta
331 variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. *Nat Med*
332 (2021). Epub 2021/10/16. doi: 10.1038/s41591-021-01548-7. PubMed PMID: 34650248.
- 333 6. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital admission
334 and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7)
335 variants of concern: a cohort study. *Lancet Infect Dis* (2021). Epub 2021/08/31. doi: 10.1016/S1473-
336 3099(21)00475-8. PubMed PMID: 34461056; PubMed Central PMCID: PMC8397301 funding from
337 GlaxoSmithKline for a research project related to seasonal influenza and antiviral treatment; this project
338 preceded and had no relation to COVID-19, and GD had no role in and received no funding from the
339 project. All other authors declare no competing interests.
- 340 7. Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2 breakthrough
341 infections in vaccinated individuals: measurement, causes and impact. *Nature Reviews Immunology*
342 (2021). doi: 10.1038/s41577-021-00662-4.
- 343 8. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and
344 transmissibility of COVID-19. *Nat Med* (2020) 26(5):672-5. Epub 2020/04/17. doi: 10.1038/s41591-020-
345 0869-5. PubMed PMID: 32296168.

- 346 9. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al. Virological
347 assessment of hospitalized patients with COVID-2019. *Nature* (2020) 581(7809):465-9. Epub
348 2020/04/03. doi: 10.1038/s41586-020-2196-x. PubMed PMID: 32235945.
- 349 10. Zapor M. Persistent Detection and Infectious Potential of SARS-CoV-2 Virus in Clinical Specimens
350 from COVID-19 Patients. *Viruses* (2020) 12(12). Epub 2020/12/09. doi: 10.3390/v12121384. PubMed
351 PMID: 33287245; PubMed Central PMCID: PMC7761721.
- 352 11. Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, et al. Enhanced isolation of
353 SARS-CoV-2 by TMPRSS2-expressing cells. *Proc Natl Acad Sci U S A* (2020) 117(13):7001-3. Epub
354 2020/03/14. doi: 10.1073/pnas.2002589117. PubMed PMID: 32165541; PubMed Central PMCID:
355 PMC7132130.
- 356 12. Monel B, Planas D, Grzelak L, Smith N, Robillard N, Staropoli I, et al. Release of infectious virus
357 and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2
358 variants: an observational retrospective study. *EBioMedicine* (2021) 73:103637. Epub 2021/10/23. doi:
359 10.1016/j.ebiom.2021.103637. PubMed PMID: 34678613; PubMed Central PMCID: PMC8526063.
- 360 13. Despres HW, Mills MG, Shirley DJ, Schmidt MM, Huang ML, Jerome KR, et al. Quantitative
361 measurement of infectious virus in SARS-CoV-2 Alpha, Delta and Epsilon variants reveals higher
362 infectivity (viral titer:RNA ratio) in clinical samples containing the Delta and Epsilon variants. *medRxiv*
363 (2021). Epub 2021/09/29. doi: 10.1101/2021.09.07.21263229. PubMed PMID: 34580674; PubMed
364 Central PMCID: PMC8475961.
- 365 14. Luo CH, Morris CP, Sachithanandham J, Amadi A, Gaston D, Li M, et al. Infection with the SARS-
366 CoV-2 Delta Variant is Associated with Higher Infectious Virus Loads Compared to the Alpha Variant in
367 both Unvaccinated and Vaccinated Individuals. *medRxiv* (2021). Epub 2021/09/01. doi:
368 10.1101/2021.08.15.21262077. PubMed PMID: 34462756; PubMed Central PMCID: PMC8404894.
- 369 15. nCoV-2019 sequencing protocol [Internet]. (2020) [cited 28 JUL 2020].
- 370 16. Viral Amplicon Illumina Workflow (VAIW): A custom pipeline to analyze the SARS-CoV-2
371 genomes prepared with an amplicon (ARTIC (v3) and YouSeq (v2)) based library protocols [Internet].
372 (2020). Available from: https://hub.docker.com/r/bdrdgenomics/viral_amplicon_illumina_workflow.
- 373 17. Bushnell B. *BBMAP: A Fast, Accurate, Splice-Aware Aligner*. (2014). p.
374 <https://sourceforge.net/projects/bbmap>.
- 375 18. Bushnell B, Rood J, Singer E. BBMerge - Accurate paired shotgun read merging via overlap. *PLoS*
376 *One* (2017) 12(10):e0185056. Epub 2017/10/27. doi: 10.1371/journal.pone.0185056. PubMed PMID:
377 29073143; PubMed Central PMCID: PMC5657622.
- 378 19. ARTIC Network Github [Internet]. (2020). Available from: [https://github.com/artic-](https://github.com/artic-network/fieldbioinformatics/tree/master/artic)
379 [network/fieldbioinformatics/tree/master/artic](https://github.com/artic-network/fieldbioinformatics/tree/master/artic).
- 380 20. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map
381 format and SAMtools. *Bioinformatics* (2009) 25(16):2078-9. Epub 2009/06/10. doi:
382 10.1093/bioinformatics/btp352. PubMed PMID: 19505943; PubMed Central PMCID: PMC2723002.
- 383 21. Grubaugh ND, Gangavarapu K, Quick J, Matteson NL, De Jesus JG, Main BJ, et al. An amplicon-
384 based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and
385 iVar. *Genome Biol* (2019) 20(1):8. Epub 2019/01/10. doi: 10.1186/s13059-018-1618-7. PubMed PMID:
386 30621750; PubMed Central PMCID: PMC6325816.
- 387 22. O'Toole A, McCrone, J.T., Scher, E. Pangolin. *GitHub* (2020).
- 388 23. Katoh K, Misawa K, Kuma K, Miyata T. MAFFT: a novel method for rapid multiple sequence
389 alignment based on fast Fourier transform. *Nucleic Acids Res* (2002) 30(14):3059-66. Epub 2002/07/24.
390 doi: 10.1093/nar/gkf436. PubMed PMID: 12136088; PubMed Central PMCID: PMC135756.
- 391 24. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et al. IQ-
392 TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. *Mol Biol Evol*

- 393 (2020) 37(5):1530-4. Epub 2020/02/06. doi: 10.1093/molbev/msaa015. PubMed PMID: 32011700;
394 PubMed Central PMCID: PMC7182206.
- 395 25. FigTree v1. 4 [Internet]. (2012). Available from: <http://tree.bio.ed.ac.uk/software/figtree/>.
- 396 26. Rambaut A, Holmes EC, O'Toole A, Hill V, McCrone JT, Ruis C, et al. A dynamic nomenclature
397 proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol* (2020). Epub
398 2020/07/17. doi: 10.1038/s41564-020-0770-5. PubMed PMID: 32669681.
- 399 27. Lubinski B, Frazier LE, Phan MVT, Bugembe DL, Tang T, Daniel S, et al. Spike protein cleavage-
400 activation mediated by the SARS-CoV-2 P681R mutation: a case-study from its first appearance in variant
401 of interest (VOI) A.23.1 identified in Uganda. *bioRxiv* (2021). Epub 2021/07/08. doi:
402 10.1101/2021.06.30.450632. PubMed PMID: 34230931; PubMed Central PMCID: PMC8259907.
- 403 28. Thomas P. Peacock CMS, Jonathan C. Brown, Niluka Goonawardane, Jie Zhou, Max Whiteley,
404 PHE Virology Consortium, Thushan I. de Silva, Wendy S. Barclay. The SARS-CoV-2 variants associated
405 with infections in INdia, B.1.617, show enhanced spike cleavage by furin. *bioRxiv* (2021). doi:
406 <https://doi.org/10.1101/2021.05.28.446163>.
- 407 29. Syed AM, Taha TY, Tabata T, Chen IP, Ciling A, Khalid MM, et al. Rapid assessment of SARS-CoV-2
408 evolved variants using virus-like particles. *Science* (2021):eabl6184. Epub 2021/11/05. doi:
409 10.1126/science.abl6184. PubMed PMID: 34735219.
- 410 30. B. Li AD, K. Li, Y. Hu, Z. Li, Q. Xiong, Z. Liu, Q. Guo, L. Zou, H. Zhang, M. Zhang, F. Ouyang, J. Su et
411 al. Viral Infection and Transmission in a large well-traced outbreak caused by the Delta SARS-CoV-2
412 variant. *medRxiv* (2021). doi: <https://doi.org/10.1101/2021.07.07.21260122>.
- 413 31. Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L, Toh M, et al. Clinical and virological features of
414 SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta),
415 and B.1.617.2 (Delta). *Clin Infect Dis* (2021). Epub 2021/08/24. doi: 10.1093/cid/ciab721. PubMed PMID:
416 34423834; PubMed Central PMCID: PMC8522361.
- 417 32. Teyssou E, Delagreverie H, Visseaux B, Lambert-Niclot S, Brichler S, Ferre V, et al. The Delta
418 SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal
419 samples from newly diagnosed COVID-19 patients. *J Infect* (2021) 83(4):e1-e3. Epub 2021/08/23. doi:
420 10.1016/j.jinf.2021.08.027. PubMed PMID: 34419559; PubMed Central PMCID: PMC8375250.
- 421 33. Kissler SM, Fauver JR, Mack C, Olesen SW, Tai C, Shiue KY, et al. Viral dynamics of acute SARS-
422 CoV-2 infection and applications to diagnostic and public health strategies. *PLoS Biol* (2021)
423 19(7):e3001333. Epub 2021/07/13. doi: 10.1371/journal.pbio.3001333. PubMed PMID: 34252080;
424 PubMed Central PMCID: PMC8297933 following competing interests: JW is an employee of Quest
425 Diagnostics. JW is an employee of Bioreference Laboratories. NDG has a consulting agreement for
426 Tempus and receives financial support from Tempus to develop SARS-CoV-2 diagnostic tests. SMK, SWO,
427 and YHG have a consulting agreement with the NBA.